Effect of Laparoscopic Sleeve Gastrectomy on Type 2 Diabetes Mellitus in Patients with Body Mass Index less than 30 kg/m2

  • Lun Wang
  • Jinfa Wang
  • Tao JiangEmail author
Original Contributions



Laparoscopic sleeve gastrectomy (LSG) has been proved to be the most effective treatment strategy for the treatment of type 2 diabetes mellitus (T2DM) with a body mass index ≥ 30 kg/m2 achieving high remission rates. However, there are few clinical studies on the treatment of T2DM patients with a body mass index less than 30 kg/m2 by LSG. This study aims to study the effect of LSG on type 2 diabetes mellitus(T2DM) in patients with a body mass index (BMI) less than 30 kg/m2.


The clinical data of 25 patients with type 2 diabetes mellitus (T2DM) and body mass index 23.23–29.97 kg/m2 who were treated by LSG at the Department of Bariatric and Metabolic Surgery in China-Japan Union Hospital of Jilin University from May 2016 to May 2017 were retrospectively analyzed. The changes of fasting plasma glucose, glycosylated hemoglobin, insulin resistance index, body weight, body mass index, waist circumference, blood pressure, heart rate, blood lipids, and uric acid were analyzed at 3 months, 6 months, and 12 months after operation, respectively. All the clinical data were analyzed by SPSS 22.0. They were tested with a single-sample K-S test to determine whether they were normal distribution data. The normal distribution data were analyzed by a matched t test, and the Mann-Whitney test was used to examine skewed data.


All patients (9 males, 16 females) with a median age of 57(24~65) years were treated successfully by laparoscopic sleeve gastrectomy. The median duration of type 2 diabetes mellitus was 10(0~20)years. The preoperative fasting plasma glucose, glycosylated hemoglobin, body weight, body mass index, and waist circumference were 10.32 ± 2.66 mmol/L,8.20 ± 1.47%,76.54 ± 10.02 kg,27.92 ± 1.72 kg/m2, and 99.88 ± 5.38 cm, respectively. The meaning fasting plasma glucose was 7.26 ± 1.36 mmol/L, 6.90 ± 1.07 mmol/L, and 6.62 ± 0.97 mmol/L, respectively, at 3, 6, and 12 months after operation. The mean HbAlc in the same observation intervals was 6.88 ± 1.23%,6.54 ± 1.02%, and 6.51 ± 0.89%, respectively. The body weight was 62.18 ± 8.38 kg,59.07 ± 8.58 kg, and 58.62 ± 8.53 kg, respectively. The corresponding body mass index was 22.56 ± 1.56 kg/m2, 21.35 ± 1.58 kg/m2, and 21.24 ± 1.86 kg/m2, respectively. The waist circumference was 82.84 ± 5.10 cm,78.60 ± 5.21 cm, and 76.92 ± 5.21 cm, respectively. The complete remission rates of type 2 diabetes mellitus were 40%, 60%, and 68%, respectively, at 3, 6, and 12 months after operation. The complete remission rates for insulin resistance index were 52.4%, 80%, and 80%, postoperatively, at 3, 6, and 12 months, respectively. The complete remission rates of hypertension were 22.2%, 50%, and 75%,respectively, at 3,6, and 12 months after operation. The complete remission rates of hypertriglyceridemia were 66.7%, 66.7%, and 100%,and the complete remission rates of hypercholesterolemia were 41.7%, 60%, and 100%;the abnormal elevations of plasma cholesterol in two patients with normal cholesterol before operation were significantly higher, postoperatively, at 3 monthsand 6 months, respectively. The complete remission rates of hyperuricemia were 37.5%, 33.3%, and 100% in the same observation period, respectively. The abnormal elevations of uric acid in two patients with normal uricemia before operation were significantly higher at postoperative 3 months.


LSG has a significant effect on patients with type 2 diabetes mellitus whose BMI less than 30 kg/m2 in a short time, but its long-term effectiveness needs to be further followed up.


Type 2 diabetes mellitus Body mass index Sleeve gastrectomy Laparoscopy 


Compliance with Ethical Standards

Statement of Human and Animal Rights

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Inform Consent

Since this is a retrospective study, formal consent is not required for this type of study.

Conflict of Interest

The authors declare that they have no conflicts of interest.


  1. 1.
    International Diabetes Federation. IDF Diabetes Atlas[DB/OL]. 8th ed 2017:41-43.
  2. 2.
    Creange C, Sethi M, Fielding G, et al. The safety of laparoscopic sleeve gastrectomy among diabetic patients. Surg Endosc. 2017;31:907–11. Scholar
  3. 3.
    Shivakumar S, Tantia O, Goyal G. LSG vs MGB-OAGB-3 Year Follow-up Data:a Randomised Control Trial. Obes Surg. 2018;28(9):2820–8. Scholar
  4. 4.
    Garg H, Priyadarshini P, Aggarwal S, et al. Comparative study of outcomes following laparoscopic Roux-en-Y gastric bypass and sleeve gastrectomy in morbidly obese patients: A case control study. World J Gastrointest Endosc. 2017;9(4):162–70. Scholar
  5. 5.
    Berry MA, Urrutia L, Lamoza P, et al. Sleeve Gastrectomy Outcomes in Patients with BMI Between 30 and 35–3 Years of Follow-Up. Obes Surg. 2018;28:649655. Scholar
  6. 6.
    Vigneshwaran B, Wahal A, Aggarwa S, et al. Impact of Sleeve Gastrectomy on Type 2 Diabetes Mellitus,Gastric Emptying Time, Glucagon-Like Peptide 1 (GLP-1),Ghrelin and Leptin in Non-morbidly Obese Subjects with BMI 30–35.0 kg/m2: a Prospective Study. Obes Surg. 2016;26:2817–23. Scholar
  7. 7.
    Hess DS, Hess DW. Biliopancreatic diversion with a duodenal switch. Obes Surg. 1998;8:267–82. Scholar
  8. 8.
    Benaiges D, Flores Le-Roux JA, Pedro-Botet J, et al. Sleeve gastrectomy and Roux-en-Y gastric bypass are equally effective in correcting insulin resistance. Int J Surg. 2013;11:309–13. Scholar
  9. 9.
    Boza C, Gamboa C, Salinas J, et al. Laparoscopic roux-en-Y gastric bypass vs laparoscopic sleeve gastrectomy and: a case control study and 3 years of follow up. Surg Obes Relat Dis. 2012;8:243–9. Scholar
  10. 10.
    Li J-F, Lai D-D, Bin N, et al. Comparison of laparoscopic Roux-en-Y gastric bypass with laparoscopic sleeve gastrectomy for morbid obesity or type 2 diabetes mellitus: a meta-analysis of randomized controlled trials. Can J Surg. 2013;56(6):158–63. Scholar
  11. 11.
    Nocca D, Guillaume F, Noel P, et al. Impact of Laparoscopic Sleeve Gastrectomy and Laparoscopic Gastric Bypass on HbA1c Blood Level and Pharmacological Treatment of Type 2 Diabetes Mellitus in Severe or Morbidly Obese Patients. Results of a Multicenter Prospective Study at 1 Year. Obes Surg. 2011;21:738–43. Scholar
  12. 12.
    Praveen RP, Bhattacharya S, Saravana Kumar S, et al. Do Bariatric Surgery-Related Type 2 Diabetes Remission Predictors Add Clinical Value? A Study on Asian Indian Obese Diabetics. Obes Surg. 2017;27:2113–9. Scholar
  13. 13.
    Moller JB, Pedersen M, Tanaka H, et al. Body composition is the main determinant for the difference in type 2 diabetes pathophysiology between Japanese and Caucasians. Diabetes Care. 2014;37:796–804. Scholar
  14. 14.
    Boffetta P, McLerran D, Chen Y, et al. Body mass index and diabetes in Asia: a cross-sectional pooled analysis of 900,000 individuals in the Asia cohort consortium. PLoS One. 2011;6:e19930. Scholar
  15. 15.
    Chambers AP, Smith EP, Begg DP, et al. Regulation of gastric emptying rate and its role in nutrient-induced GLP-1 secretion in rats after vertical sleeve gastrectomy. Am J Physiol Endocrinol Metab. 2014;306(4):E424–32. Scholar
  16. 16.
    Morinigo R, Moize V, Mustri M, et al. GLP-1,PYY, hunger and satiety following gastric bypass surgery in morbidly obese subjects. J Clin Endocrinol Metab. 2006;91(5):1735–40. Scholar
  17. 17.
    Sista F, Abruzzese V, Clementi M, et al. Effect of Resected Gastric Volume on Ghrelin and GLP-1 Plasma Levels: a Prospective Study. J Gastrointest Surg. 2016;20:1931–41. Scholar
  18. 18.
    Langer FB, Reza Hoda MA, Bohdjalian A, et al. Sleeve gastrectomy and gastric banding effects on plasma ghrelin levels. Obes Surg. 2005;15(7):1021–9. Scholar
  19. 19.
    Guo Y, Xu X, Wu A, et al. Effect of laparoscopic sleeve gatrectomy on type 2 diabetes mellitus in obese patients with body mass index less than 40 kg/m2. Chin J Gastrointest. 2017;20(4):400–3. Scholar
  20. 20.
    Lee WJ, Hur KY, Lakadawala M, et al. Predicting success of metabolic surgery: age, body mass index, C-peptide, and duration score. Surg Obes Relat Dis. 2013;9:379–84. Scholar
  21. 21.
    Janik MR, Waledziak M, Bragoszewski J, et al. Prediction model for hemorrhagic complications after laparoscopic sleeve gastrectomy:development of sleeve Bleed calculator. Obes Surg. 2017;27(4):968–72. Scholar
  22. 22.
    Abdallah E, Emile SH, Elfeki H. Laparoscopic sleeve gastrectomy with or without staple line inversion and distal fixation to the transverse mesocolon: impact on early postoperativeoutcomes. ObesSurg. 2017;27(2):323–9. Scholar
  23. 23.
    Kim SB, Kim SM. Short-Term Analysis of Food Tolerance and Quality of Life after Laparoscopic Greater Curvature Plication. Yonsei Med J. 2016;57(2):430–40. Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Bariatric and Metabolic Surgery, China-Japan Union HospitalJilin UniversityChangchunChina

Personalised recommendations